Jiangsu Aidea Pharmaceutical Co Ltd (688488) — Working Capital to Net Assets Ratio
Jiangsu Aidea Pharmaceutical Co Ltd (688488) has a Working Capital to Net Assets ratio of 24.4% as of September 2025. Working capital of CN¥263.87 Million (current assets of CN¥895.79 Million minus current liabilities of CN¥631.92 Million) is measured against net assets of CN¥1.08 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial agility of Jiangsu Aidea Pharmaceutical Co Ltd to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Jiangsu Aidea Pharmaceutical Co Ltd Working Capital to Net Assets (2016–2024)
This chart shows how Jiangsu Aidea Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2016 to 2024. As of September 2025, the ratio stands at 24.4%, reflecting working capital of CN¥263.87 Million against net assets of CN¥1.08 Billion CNY. See Jiangsu Aidea Pharmaceutical Co Ltd (688488) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Jiangsu Aidea Pharmaceutical Co Ltd (2016–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2024, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Jiangsu Aidea Pharmaceutical Co Ltd (688488) market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 23.0% | CN¥245.87 Million | CN¥1.07 Billion | CN¥894.93 Million | CN¥649.06 Million | ▼ -10.8 pp |
| 2023 | 33.8% | CN¥380.81 Million | CN¥1.13 Billion | CN¥872.38 Million | CN¥491.57 Million | ▼ -5.4 pp |
| 2022 | 39.3% | CN¥470.78 Million | CN¥1.20 Billion | CN¥802.46 Million | CN¥331.68 Million | ▼ -16.8 pp |
| 2021 | 56.1% | CN¥734.39 Million | CN¥1.31 Billion | CN¥826.93 Million | CN¥92.54 Million | ▼ -12.6 pp |
| 2020 | 68.7% | CN¥933.72 Million | CN¥1.36 Billion | CN¥1.01 Billion | CN¥73.00 Million | ▲ +40.1 pp |
| 2019 | 28.6% | CN¥158.99 Million | CN¥556.24 Million | CN¥368.11 Million | CN¥209.13 Million | ▲ +2.7 pp |
| 2018 | 25.9% | CN¥135.25 Million | CN¥522.71 Million | CN¥310.36 Million | CN¥175.11 Million | ▼ -7.5 pp |
| 2017 | 33.4% | CN¥171.66 Million | CN¥514.09 Million | CN¥305.07 Million | CN¥133.42 Million | ▲ +21.0 pp |
| 2016 | 12.3% | CN¥37.09 Million | CN¥300.40 Million | CN¥167.05 Million | CN¥129.96 Million | — |